第九届董事会第二次会议决议公告 共 6 页 证券代码：000931 证券简称：中关村 公告编号：2025-038 北京中关村科技发展（控股）股份有限公司 第九届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 北京中关村科技发展（控股）股份有限公司（以下简称：公司）第九届董事 会第二次会议通知于 2025 年 4 月 7 日以专人送达、电子邮件或传真等方式发出， 会议于 2025 年 4 月 16 日上午 10 时在北京市朝阳区霄云路 26 号鹏润大厦 B 座 22 层 1 号会议室以现场结合通讯表决方式如期召开。会议应到董事 9 名，实到 董事 9 名。会议召开程序符合相关法律法规和《公司章程》的有关规定。经与会 董事认真讨论研究，形成以下决议： 一、审议通过《2024 年年度报告全文及摘要》； 表决结果：9 票同意，0 票反对，0 票弃权。 《2024 年度财务报告》已经董事会审计委员会审议通过。 具体内容详见与本公告同日披露的《2024 年年度报告》《2024 年年度报告 摘要》（公告编号：2025-040、041），本议案须提交 ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion yuan, representing a year-over-year growth of 15%[18]. - The company's operating revenue for 2024 reached ¥2,532,142,197.75, representing an increase of 11.22% compared to ¥2,276,603,345.75 in 2023[26]. - The net profit attributable to shareholders for 2024 was ¥53,592,190.23, up 10.33% from ¥48,781,604.61 in 2023[26]. - The company achieved consolidated revenue of 2.532 billion yuan, an increase of 11.22% year-on-year, and a net profit attributable to shareholders of 53.59 million yuan, up 10.33% year-on-year[66]. - The company reported a gross margin of 45%, up from 40% in the previous year, indicating improved operational efficiency[9]. - The total operating revenue for the reporting period reached ¥2,532,142,197.75, representing an increase of 11.22% compared to ¥2,276,603,345.75 in the previous year[83]. User Growth and Market Expansion - User data indicates a growth in active users, reaching 5 million, which is a 20% increase compared to the previous year[18]. - User data showed a 25% increase in active users, totaling 5 million users by the end of the quarter[2]. - The company has outlined its future outlook, projecting a revenue growth of 10% for the next fiscal year, driven by new product launches and market expansion strategies[18]. - Future outlook indicates a projected revenue growth of 15% for the next fiscal year, driven by new product launches and market expansion[199]. - Market expansion plans include entering three new international markets by Q3 2024, targeting a 10% increase in global market share[6]. - Market expansion plans include entering three new international markets by Q3 2024, aiming for a 10% market share in each[199]. Research and Development - Investment in R&D has increased by 25%, focusing on innovative technologies and new product development to enhance market competitiveness[18]. - The company is investing $50 million in R&D for new technologies aimed at enhancing product efficiency[5]. - R&D investment amounted to ¥114,040,208.16 in 2024, an increase of 6.81% compared to ¥106,773,729.12 in 2023[103]. - The company is developing new products such as sodium bromhexine injection and febuxostat tablets to enhance its product lineup in the cold and gout medication sectors[101]. - The company aims to enhance its cardiovascular product line with new offerings like bisoprolol and amlodipine tablets, which are currently in the approval process[101]. Acquisitions and Strategic Initiatives - A strategic acquisition of a local tech firm is in progress, expected to enhance the company's technological capabilities and product offerings[18]. - The company completed a strategic acquisition of a smaller competitor for $300 million, expected to enhance its product portfolio[7]. - The company successfully acquired 51% of Chengdu Internet Hospital, aligning with its strategic focus on "precision nutrition" business models[77]. - The company acquired 51% of Chengdu Wenjiang Guomei Internet Hospital Co., Ltd., making it a controlled subsidiary, and also completed several other acquisitions to expand its portfolio[92]. Financial Management and Investments - The company has decided not to distribute cash dividends or issue bonus shares for this fiscal year, opting to reinvest profits into growth initiatives[7]. - The company reported a significant increase in fixed asset purchases, totaling CNY 113,421,500.00, up 68.47% year-on-year[109]. - The total amount of loans secured by various properties and assets indicates a strong reliance on collateral for financing[126]. - The company’s total investment amount for the reporting period was 26.6 million yuan, a decrease of 51.03% compared to the same period last year, which was 54.32 million yuan[134]. Elderly Care Services - The company has developed a five-in-one elderly care ecosystem, enhancing its presence in the elderly care industry since launching its elderly care business in 2017[41]. - The "Nalan Garden" elderly care project received a four-star rating from the Beijing Elderly Care Service Quality Star Rating Committee, showcasing the quality of its services[41]. - The company is actively expanding its elderly care services, with the new hospital site construction progressing, which will double its operational space[42]. - The company has been awarded multiple honors, including being listed among the top 100 private manufacturing enterprises in Heilongjiang Province, reflecting its strong market performance[40]. Governance and Compliance - The company has established a robust governance structure that complies with legal and regulatory requirements, with no significant discrepancies noted[179]. - The company has implemented a cumulative voting system to reflect minority shareholders' opinions during board elections[172]. - The company adheres to legal requirements for shareholder meetings, ensuring equal rights for all shareholders[170]. - The company has established a dedicated information disclosure mechanism, ensuring timely and accurate communication with investors through various channels[177]. Future Outlook - The company has outlined its future outlook, projecting a revenue growth of 10% for the next fiscal year, driven by new product launches and market expansion strategies[18]. - The company aims for consolidated revenue and net profit attributable to shareholders to grow in 2025 compared to 2024[152]. - The company will focus on enhancing sales capabilities and controlling expenses in the biopharmaceutical and health products business, while also seeking new projects and products for profit growth[152]. - The company will continue to focus on mRNA and antibody technology for innovative biopharmaceuticals targeting infectious diseases, pushing products into clinical stages in 2025[154].

关于 2024 年度利润分配预案公告 共 3 页 证券代码：000931 证券简称：中关村 公告编号：2025-042 北京中关村科技发展（控股）股份有限公司 关于 2024 年度利润分配预案公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 经中兴财光华会计师事务所（特殊普通合伙）审计，公司 2024 年实现归属 于上市公司股东的净利润 53,592,190.23 元，母公司净利润-68,156,162.51 元。截 至 2024 年 12 月 31 日，公司合并报表未分配利润-796,367,861.42 元，母公司报 表未分配利润-1,254,721,547.03 元。 鉴于公司 2024 年度公司合并报表、母公司报表中累计未分配利润均为负值， 不具备现金分红的前提条件，故公司 2024 年度拟不进行利润分配，亦不实施资 本公积金转增股本和其他形式的分配。 三、现金分红方案的具体情况 第 1 页 项 目 本年度 上年度 上上年度 现金分红总额（元） 0.00 0.00 0.00 回购注销总额（元） 0.00 0.00 0.00 归属于上市公司股东的净利 ...

Group 1: Innovation Ecosystem in Xiong'an New Area - The Xiong'an New Area is witnessing rapid development in industries such as artificial intelligence, robotics, and the metaverse, with a focus on collaborative innovation [1][2] - The R&D investment intensity in the Beijing-Tianjin-Hebei region has increased from 3.22% in 2013 to 4.27% in 2023, surpassing the national average by 1.62 percentage points [1] - Over 140 companies have settled in the Xiong'an New Area's Zhongguancun Science Park, including industry leaders and high-growth tech firms, creating a "class Zhongguancun" innovation ecosystem [2] Group 2: Technological Advancements and Applications - Zhaofu (Xiong'an) Technology Co., Ltd. has developed internationally leading nuclear radiation multi-modal smart wearable devices, showcasing the potential of the innovation ecosystem [2] - Huahui Chip Technology Group has created the world's first real-time hyperspectral imaging chip, with over 50 patented products serving more than 600 research institutions and enterprises [3][4] - The "Smart Ultrasound Remote Consultation System" developed by It Si Technology has been deployed in hospitals, enhancing remote medical consultations [4] Group 3: Industrial Collaboration and Development - Beijing Jingdiao Technology Group has established a three-region manufacturing model, significantly increasing production efficiency and output of precision machine tools [6] - The Xiong'an New Area is evolving from being an "executor" to a "co-creator" in industrial chains, with over 150 companies signed in the Xianghe Robot Town [7] - The region is focusing on deep collaboration in technology transfer and industrialization, with a total of 467 technology contracts worth 14.492 billion yuan signed in Langfang [7] Group 4: Policy and Strategic Recommendations - There is a need for unified policy coordination among Beijing, Tianjin, and Hebei to facilitate talent mobility and enhance the economic effects of technology transfer [8][9] - The integration of traditional industry upgrades and emerging industry cultivation is reshaping the development landscape of the Beijing-Tianjin-Hebei region [8] - Emphasis on both technological innovation and industrial innovation is crucial for injecting new momentum into regional industrial development [9]

关于下属公司山东华素比索洛尔氨氯地平片收到国家药品监督管理局《受理通知书》的公告 共 2 页 证券代码：000931 证券简称：中关村 公告编号：2025-037 北京中关村科技发展（控股）股份有限公司 关于下属公司山东华素比索洛尔氨氯地平片收到国家 药品监督管理局《受理通知书》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 北京中关村科技发展（控股）股份有限公司（以下简称：公司）下属公司 山东华素制药有限公司（以下简称：山东华素）于近日收到国家药品监督管理 局（以下简称：国家药监局）签发的《受理通知书》，比索洛尔氨氯地平片（规 格：富马酸比索洛尔 5mg 与苯磺酸氨氯地平（按氨氯地平计）5mg）上市许可 申请获得受理，现将相关情况公告如下： 一、基本信息 药品名称：比索洛尔氨氯地平片 剂型：片剂 规格：富马酸比索洛尔 5mg 与苯磺酸氨氯地平（按氨氯地平计）5mg 申请事项：境内生产药品注册上市许可 注册分类：化学药品 4 类 申请人：山东华素制药有限公司 受理号：CYHS2501423 结论：经审查，决定予以受理。 二、药品其他相关情况 比索洛尔氨 ...

Core Viewpoint - Zhongguancun announced that its subsidiary Shandong Huasu Pharmaceutical Co., Ltd. has had its application for the listing permit of Bisoprolol Amlodipine Tablets accepted by the National Medical Products Administration, which is a combination therapy for hypertension treatment [1] Group 1 - The drug is a fixed-dose combination formulation of fumarate bisoprolol 5mg and amlodipine besylate (calculated as amlodipine) 5mg [1] - The project has accumulated research and development expenses of 6.0798 million yuan [1] - Shandong Huasu will actively promote the subsequent review work, and if the listing permit is successfully obtained, it will enhance its market competitiveness [1]

Core Insights - Penghui Energy launched two strategic new products, the Fengpeng 600Ah+ large cell and the commercial energy storage cabinet "Qingtian 520," at the Beijing Zhongguancun Energy Storage International Summit and Exhibition, addressing key pain points in the energy storage industry [1][3][10] Group 1: Fengpeng 600Ah+ Large Cell - The Fengpeng 600Ah+ large cell is designed for power storage scenarios, emphasizing reliability and innovation as core attributes [3][6] - Key features include: - Full temperature range efficiency: over 84% at 5°C, over 94.5% at 25°C, and nearly 96% at 45°C [6] - Ultra-long cycle life exceeding 10,000 cycles, leading the industry [6] - Triple safety protection mechanisms, including: - Nano shield technology for thermal runaway prevention [6] - Gel flame-retardant electrolyte for fire suppression [6] - Honeycomb carbon cooling technology for enhanced thermal management [6] - The industry is entering a "Double Six Era," marked by the integration of 600Ah+ cells and 6MWh+ systems [6][10] Group 2: Qingtian 520 Energy Storage Cabinet - The Qingtian 520 energy storage cabinet features a capacity of 520kWh, utilizing self-developed 314Ah "Fengpeng" cells, with a 32.5% increase in energy density [7] - It offers a 54% reduction in footprint compared to traditional solutions and supports flexible deployment [7] - Overall energy efficiency reaches 90%, surpassing the industry average of 86%, with a 4% improvement [7] - The launch signifies a shift in commercial energy storage from "scalability" to "value" [7][10] Group 3: Company Strategy and Industry Impact - The launch of these products reflects Penghui Energy's "scenario-based energy storage" strategy, focusing on the efficiency of the entire chain from cells to systems to applications [10] - The company has been deeply involved in the battery industry for 24 years and was an early player in the energy storage sector since 2011, emphasizing "technology for all" [12] - The theme of the exhibition, "TechG Technology Penghui," showcases the company's robust energy storage technology capabilities, contributing to global carbon neutrality goals [12]

Group 1 - The core point of the report indicates that the Jianxin Zhongguancun REIT experienced a significant decline in revenue and incurred substantial losses during the reporting period [1][2] - The fund's revenue for 2024 was approximately 138 million, representing a year-on-year decrease of about 20% compared to 173 million in 2023 [2] - The net loss for the period was approximately 332 million, with goodwill impairment losses of about 8.45 million and investment property impairment losses of around 318 million, totaling 403 million [1][2] Group 2 - As of the end of 2024, the total assets of the fund were approximately 2.64 billion, down from 3.13 billion in 2023, while net assets were about 1.98 billion, compared to 2.38 billion in the previous year [2] - The occupancy rate of the underlying infrastructure projects improved to 72.09% as of December 31, 2024, an increase of 8.34 percentage points from 63.75% in the previous year, reflecting a year-on-year rise of 13.08% [2] - The average monthly rental income for the infrastructure projects decreased by 17.66% year-on-year during the reporting period, and the distributable amount for the fund fell by 48.20% [5]

《工作要点》指出，聚焦平原新城、京西、南中轴等未来发展新增长点，今年北京将继续提升重点区域 发展能级。其中，在平原新城建设方面，将推动R4线一期北段等轨道交通快线开工，打造新龙泽等轨 道微中心，加快建设未来大学科技园、大兴国际氢能合作示范区等高质量创新和产业空间等。 中新社北京4月7日电 (记者 吕少威)2025年北京将重点支持河北雄安新区创新能力建设，推动一批新技 术新产品在雄安新区孵化转化，实现不少于60家高成长型企业落地雄安新区中关村科技园。这是记者7 日从北京市发展和改革委员会了解到的。 在京西地区建设方面，北京将重点推进"两园一河"(首钢园、园博园、永定河)先行启动区建设，聚焦永 定河左岸建设和道路连通，落地一批标志性项目，打造首钢园服贸会"会展小镇"。(完) 雄安新区中关村科技园于2023年8月30日揭牌，以新一代信息技术、现代生命科学和生物技术、空天信 息、人工智能、新材料为产业主导，超前布局新技术、新产品先行先试应用场景。开园一年多来，已吸 引140多家企业入驻，其中既有行业龙头企业和专精特新"小巨人"企业，也有高成长性的科技型企业。 根据北京市发展和改革委员会发布的《进一步推动首都高质量发展 ...

日前，100亿元规模的中关村战新基金发布，重庆设立首只S母基金。此外，广州上市公司高质量发展基 金落地首只子基金，宁波成立一只光学产业基金。 百亿中关村战新基金发布 近日，在2025中关村论坛年会硬科技投资与发展论坛上，100亿元规模的中关村战新基金发布，该基金在 北京市西城区、北京国有资本运营管理有限公司的支持下，由中关村发展集团联合新华人寿保险股份有 限公司、工银金融资产投资有限公司等多家意向单位共同筹划设立。 据介绍，该基金将聚焦战略性新兴产业，为一批优质硬科技企业加速发展提供金融支持。 中金资本设立一只氢能基金 日前，中金资本作为管理人及普通合伙人，与辛集建设投资有限公司、河北省科技金融发展促进中心共 同发起设立中金（辛集市）氢能创业投资基金合伙企业（有限合伙）（以下简称"中金辛集氢能基 金"）。 该基金将围绕辛集市氢能产业微循环打造，主要投向从事氢燃料电池整机、新材料、核心零部件、氢 能"制、储、运、加、用"等环节装备制造及相关科技企业。基金规模5亿元，已于近日在中国证券投资基 金业协会完成备案。 重庆首只S母基金来了 近日，中国银河投资与重庆科创投签约，共同发起设立重庆首只S母基金--重庆渝创银河 ...